Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response-Reference-Cited by-同舟云学术

Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response

Published:2024-05-25 Issue:6 Volume:316 Page:
ISSN:1432-069X
Container-title:Archives of Dermatological Research
language:en
Short-container-title:Arch Dermatol Res

Author:

Li Shanshan,Zhao Junjie,Wang Guangyu,Yao Qingping,Leng Zhe,Liu Qinglei,Jiang Jun,Wang Wei

Funder

the young and middle-aged talent development fund of Shanghai Institute of Technology

National Natural Science Foundation of China

the Science & Technology Department of Sichuan Province

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00403-024-03080-3.pdf

Reference59 articles.

1. Liu Y, Zhang H, Hu D, Liu S (2023) New algorithms based on autophagy-related lncRNAs pairs to predict the prognosis of skin cutaneous melanoma patients. Arch Dermatol Res 9:1–6. https://doi.org/10.1007/s00403-022-02522-0

2. Carr S, Smith C, Wernberg J (2020) Epidemiology and risk factors of melanoma. Surg Clin North Am 100:1–2. https://doi.org/10.1016/j.suc.2019.09.005

3. Bagge RO, Ny L, Ascierto PA, Hodi FS, Larkin J, Robert C, Schachter J, Weber JS, Long GV, Van Akkooi AC (2021) The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. Melanoma Res 31:181–185. https://doi.org/10.1097/CMR.0000000000000719

4. Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C (2020) Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis. JAMA Oncol 6:375–384. https://doi.org/10.1001/jamaoncol.2019.5367

5. Nakamura K, Ashida A, Kiniwa Y, Okuyama R (2022) Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. Arch Dermatol Res 314:887–895. https://doi.org/10.1007/s00403-021-02305-z